Israel Englander Lumos Pharma, Inc. Transaction History

Millennium Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.19 - $3.04 $1,228 - $1,705	-561 Reduced 1.49%	37,018 $85,000
Q1 2024 May 15, 2024	BUY	$2.64 - $3.22 $99,208 - $121,004	37,579 New	37,579 $105,000
Q2 2023 Aug 14, 2023	SELL	$3.01 - $4.38 $58,400 - $84,980	-19,402 Reduced 56.5%	14,940 $49,000
Q1 2023 May 15, 2023	BUY	$3.16 - $4.0 $45,203 - $57,220	14,305 Added 71.39%	34,342 $116,000
Q4 2022 Feb 14, 2023	BUY	$3.05 - $9.52 $61,112 - $190,752	20,037 New	20,037 $72,000
Q4 2021 Feb 14, 2022	SELL	$6.84 - $10.04 $104,980 - $154,093	-15,348 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$7.36 - $11.36 $112,961 - $174,353	15,348 New	15,348 $146,000
Q2 2020 Aug 14, 2020	SELL	$7.76 - $16.99 $293,017 - $641,542	-37,760 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.89 - $8.85 $33,606 - $334,176	37,760 New	37,760 $321,000

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.